Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment

CONTEXT Hydroxyurea increases levels of fetal hemoglobin (HbF) and decreases morbidity from vaso-occlusive complications in patients with sickle cell anemia (SCA). High HbF levels reduce morbidity and mortality. OBJECTIVE To determine whether hydroxyurea attenuates mortality in patients with SCA. DE...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA : the journal of the American Medical Association 2003-04, Vol.289 (13), p.1645-1651
Hauptverfasser:	Steinberg, Martin H, Barton, Franca, Castro, Oswaldo, Pegelow, Charles H, Ballas, Samir K, Kutlar, Abdullah, Orringer, Eugene, Bellevue, Rita, Olivieri, Nancy, Eckman, James, Varma, Mala, Ramirez, Gloria, Adler, Brian, Smith, Wally, Carlos, Timothy, Ataga, Kenneth, DeCastro, Laura, Bigelow, Carolyn, Saunthararajah, Yogen, Telfer, Margaret, Vichinsky, Elliott, Claster, Susan, Shurin, Susan, Bridges, Kenneth, Waclawiw, Myron, Bonds, Duane, Terrin, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anemia, Sickle Cell - drug therapy Anemia, Sickle Cell - mortality Anemia, Sickle Cell - physiopathology Antisickling Agents - therapeutic use Biological and medical sciences Blood Cell Count Blood. Blood coagulation. Reticuloendothelial system Cause of Death Clinical outcomes Double-Blind Method Drug therapy Fetal Hemoglobin - metabolism Follow-Up Studies Humans Hydroxyurea - therapeutic use Medical sciences Morbidity Mortality Pharmacology. Drug treatments Risk Assessment Sickle cell anemia Survival Analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!